Literature DB >> 24719459

Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression.

Andrew W Woodham1, Adam B Raff, Laura M Raff, Diane M Da Silva, Lisa Yan, Joseph G Skeate, Michael K Wong, Yvonne G Lin, W Martin Kast.   

Abstract

High-risk human papillomaviruses (HPVs) are sexually transmitted viruses causally associated with several cancers. During its natural life cycle, HPV16, the most common high-risk genotype, infects the epithelial basal cells in a process facilitated through a recently identified receptor, the annexin A2 heterotetramer (A2t). During infection, HPV16 also interacts with Langerhans cells (LC), the APC of the epithelium, inducing immune suppression, which is mediated by the HPV16 L2 minor capsid protein. Despite the importance of these virus-immune cell interactions, the specific mechanisms of HPV16 entry into LC and HPV16-induced immune suppression remain undefined. An N-terminal peptide of HPV16 L2 (aa 108-126) has been shown to specifically interact with A2t. In this study, we show that incubation of human LC with this peptide blocks binding of HPV16. Inhibiting this interaction with an A2t ligand or by small interfering RNA downregulation of A2t significantly decreases HPV16 internalization into LC in an L2-dependent manner. A2t is associated with suppression of LC maturation as demonstrated through attenuated secretion of Th1-associated cytokines and decreased surface expression of MHC class II on LC exposed to A2t. Conversely, small molecule inhibition of A2t prevents HPV16-induced suppression of LC immune function as indicated by significantly increased secretion of inflammatory cytokines and surface expression of CD86 in HPV16 treated LC pre-exposed to A2t inhibitors. These results demonstrate that HPV16 suppresses LC maturation through an interaction with A2t, revealing a novel role for this protein.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24719459      PMCID: PMC4019435          DOI: 10.4049/jimmunol.1303190

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  84 in total

1.  Type I gamma phosphatidylinositol phosphate kinase targets and regulates focal adhesions.

Authors:  Kun Ling; Renee L Doughman; Ari J Firestone; Matthew W Bunce; Richard A Anderson
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

2.  A protective and broadly cross-neutralizing epitope of human papillomavirus L2.

Authors:  Ratish Gambhira; Balasubramanyam Karanam; Subhashini Jagu; Jeffrey N Roberts; Christopher B Buck; Ioannis Bossis; Hannah Alphs; Timothy Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

Review 3.  HPV: from infection to cancer.

Authors:  M A Stanley; M R Pett; N Coleman
Journal:  Biochem Soc Trans       Date:  2007-12       Impact factor: 5.407

4.  Arrangement of L2 within the papillomavirus capsid.

Authors:  Christopher B Buck; Naiqian Cheng; Cynthia D Thompson; Douglas R Lowy; Alasdair C Steven; John T Schiller; Benes L Trus
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

5.  Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11.

Authors:  Kai-Li He; Arunkumar B Deora; Huabao Xiong; Qi Ling; Babette B Weksler; Ruben Niesvizky; Katherine A Hajjar
Journal:  J Biol Chem       Date:  2008-04-23       Impact factor: 5.157

6.  Production of papillomavirus-based gene transfer vectors.

Authors:  Christopher B Buck; Cynthia D Thompson
Journal:  Curr Protoc Cell Biol       Date:  2007-12

Review 7.  S100A10/p11: family, friends and functions.

Authors:  Ursula Rescher; Volker Gerke
Journal:  Pflugers Arch       Date:  2007-07-19       Impact factor: 3.657

8.  Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity.

Authors:  Diane M Da Silva; Steven C Fausch; J Sjef Verbeek; W Martin Kast
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

9.  Recruitment and regulation of phosphatidylinositol phosphate kinase type 1 gamma by the FERM domain of talin.

Authors:  Gilbert Di Paolo; Lorenzo Pellegrini; Kresimir Letinic; Gianluca Cestra; Roberto Zoncu; Sergei Voronov; Sunghoe Chang; Jun Guo; Markus R Wenk; Pietro De Camilli
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

Review 10.  Human papillomavirus type 16 late gene expression is regulated by cellular RNA processing factors in response to epithelial differentiation.

Authors:  Sarah A Cumming; Thanaporn Cheun-Im; Stephen G Milligan; Sheila V Graham
Journal:  Biochem Soc Trans       Date:  2008-06       Impact factor: 5.407

View more
  21 in total

Review 1.  Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment.

Authors:  Andrew W Woodham; Joseph G Skeate; Adriana M Sanna; Julia R Taylor; Diane M Da Silva; Paula M Cannon; W Martin Kast
Journal:  AIDS Patient Care STDS       Date:  2016-07       Impact factor: 5.078

Review 2.  Evasion of host immune defenses by human papillomavirus.

Authors:  Joseph A Westrich; Cody J Warren; Dohun Pyeon
Journal:  Virus Res       Date:  2016-11-24       Impact factor: 3.303

3.  Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype.

Authors:  Diane M Da Silva; Carly A Movius; Adam B Raff; Heike E Brand; Joseph G Skeate; Michael K Wong; W Martin Kast
Journal:  Virology       Date:  2014-02-17       Impact factor: 3.616

4.  Annexin A2 Regulates Autophagy in Pseudomonas aeruginosa Infection through the Akt1-mTOR-ULK1/2 Signaling Pathway.

Authors:  Rongpeng Li; Shirui Tan; Min Yu; Michael C Jundt; Shuang Zhang; Min Wu
Journal:  J Immunol       Date:  2015-09-14       Impact factor: 5.422

5.  Immunology of Uterine and Vaginal Mucosae: (Trends in Immunology 39, 302-314, 2018).

Authors:  Jordan Z Zhou; Sing Sing Way; Kang Chen
Journal:  Trends Immunol       Date:  2018-03-09       Impact factor: 16.687

6.  Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C.

Authors:  Diane M Da Silva; Andrew W Woodham; Joseph G Skeate; Laurie K Rijkee; Julia R Taylor; Heike E Brand; Laila I Muderspach; Lynda D Roman; Annie A Yessaian; Huyen Q Pham; Koji Matsuo; Yvonne G Lin; Greg M McKee; Andres M Salazar; W Martin Kast
Journal:  Clin Immunol       Date:  2015-09-08       Impact factor: 3.969

7.  Secretory Leukocyte Protease Inhibitor Expression and High-Risk HPV Infection in Anal Lesions of HIV-Positive Patients.

Authors:  Alcina F Nicol; Laurie L Brunette; Gerard J Nuovo; Beatriz Grinsztejn; Ruth K Friedman; Valdiléa G Veloso; Cynthia B Cunha; José R Coutinho; Cecilia Vianna-Andrade; Nathalia S Oliveira; Andrew W Woodham; Diane M DA Silva; W Martin Kast
Journal:  J Acquir Immune Defic Syndr       Date:  2016-09-01       Impact factor: 3.731

Review 8.  Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.

Authors:  Joseph G Skeate; Andrew W Woodham; Mark H Einstein; Diane M Da Silva; W Martin Kast
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

9.  Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection.

Authors:  Joseph G Skeate; Tania B Porras; Andrew W Woodham; Julie K Jang; Julia R Taylor; Heike E Brand; Thomas J Kelly; Jae U Jung; Diane M Da Silva; Weiming Yuan; W Martin Kast
Journal:  J Gen Virol       Date:  2015-11-10       Impact factor: 3.891

10.  ANXA2 Facilitates Enterovirus 71 Infection by Interacting with 3D Polymerase and PI4KB to Assist the Assembly of Replication Organelles.

Authors:  Qiuhan Zhang; Siliang Li; Ping Lei; Zixian Li; Feifei Chen; Qi Chen; Yulu Wang; Jiami Gong; Qi Tang; Xinjin Liu; Ke Lan; Shuwen Wu
Journal:  Virol Sin       Date:  2021-07-01       Impact factor: 6.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.